| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |